🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

65,67 USD

Máx. histórico

89,55

119 días

Caída desde máximo

-26,67%

Rango 52 semanas

58,80 – 90,87

Variación hoy

-4,79%

Cierre anterior

68,97

Rango de hoy

65,45 – 69,59

Volumen hoy

1.228.468

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 7 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
02/03/2020 55,00 55,23 52,72 54,93 +0,16% 4,56% 1.686.300
28/02/2020 51,86 54,84 51,86 54,84 +2,43% 5,75% 939.500
27/02/2020 53,24 57,37 51,41 53,54 -1,47% 11,19% 1.050.300
26/02/2020 53,21 55,44 53,01 54,34 +2,88% 4,57% 733.000
25/02/2020 55,33 55,87 52,15 52,82 -3,77% 6,73% 917.500
24/02/2020 55,50 56,44 54,49 54,89 -4,00% 3,51% 1.607.400
21/02/2020 57,46 57,68 55,00 57,18 -0,30% 4,66% 1.088.400
20/02/2020 57,47 58,14 55,66 57,35 -3,39% 4,32% 1.250.200
19/02/2020 58,36 59,89 58,35 59,36 +1,71% 2,65% 729.500
18/02/2020 57,74 58,95 56,54 58,36 +1,06% 4,17% 461.500
14/02/2020 56,83 58,44 56,63 57,75 +1,73% 3,18% 554.800
13/02/2020 57,50 58,00 56,40 56,77 -1,80% 2,78% 567.400
12/02/2020 56,61 58,45 56,25 57,81 +2,97% 3,88% 758.400
11/02/2020 55,81 56,89 54,99 56,14 +1,67% 3,41% 788.000
10/02/2020 53,92 55,31 53,72 55,22 +2,66% 2,96% 637.500
07/02/2020 54,11 54,46 51,63 53,79 -2,08% 5,22% 1.234.100
06/02/2020 47,00 55,21 46,80 54,94 +2,91% 17,89% 3.660.800
05/02/2020 54,36 55,00 52,16 53,38 -0,67% 5,22% 948.000
04/02/2020 53,00 54,41 52,42 53,74 +2,85% 3,77% 1.063.100
03/02/2020 52,03 52,30 51,04 52,25 +1,46% 2,42% 1.013.900
31/01/2020 51,25 51,93 50,48 51,50 +0,53% 2,83% 530.900
30/01/2020 50,39 51,55 50,06 51,23 +0,14% 2,96% 730.600
29/01/2020 51,71 52,09 51,12 51,16 -0,72% 1,88% 458.000
28/01/2020 51,46 52,46 50,64 51,53 +0,86% 3,54% 645.000
27/01/2020 50,90 51,56 50,21 51,09 -1,60% 2,65% 1.322.800
24/01/2020 53,56 53,88 51,81 51,92 -2,64% 3,86% 501.300
23/01/2020 53,75 53,75 52,37 53,33 -0,76% 2,57% 789.600
22/01/2020 52,88 54,17 52,18 53,74 +0,43% 3,76% 775.300
21/01/2020 53,27 54,37 53,08 53,51 -0,54% 2,42% 925.200
17/01/2020 52,84 53,85 52,56 53,80 +2,53% 2,44% 780.000